Advanced search
1 file | 84.87 KB Add to list

A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)

(2020) ANNALS OF ONCOLOGY. 31(Suppl 4). p.S897-S898
Author
Organization

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 84.87 KB

Citation

Please use this url to cite or link to this publication:

MLA
Reck, M., et al. “A Phase I/II Trial of Radium-223 (Ra-223) in Combination with Pembrolizumab in Patients (Pts) with Stage IV Non-Small Cell Lung Cancer (NSCLC).” ANNALS OF ONCOLOGY, vol. 31, no. Suppl 4, Elsevier, 2020, pp. S897–98, doi:10.1016/j.annonc.2020.08.1734.
APA
Reck, M., Mileham, K. F., Clump, D. A., Decoster, L., Estival, A., Felip, E., … Smit, E. F. (2020). A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 31(Suppl 4), S897–S898. https://doi.org/10.1016/j.annonc.2020.08.1734
Chicago author-date
Reck, M., K. F. Mileham, D. A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, et al. 2020. “A Phase I/II Trial of Radium-223 (Ra-223) in Combination with Pembrolizumab in Patients (Pts) with Stage IV Non-Small Cell Lung Cancer (NSCLC).” In ANNALS OF ONCOLOGY, 31:S897–98. Amsterdam: Elsevier. https://doi.org/10.1016/j.annonc.2020.08.1734.
Chicago author-date (all authors)
Reck, M., K. F. Mileham, D. A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, L. Paz-Ares, M. Sebastian, N Vinolas Segarra, Veerle Surmont, A. Wagner, S. M. Galdy, and E. F. Smit. 2020. “A Phase I/II Trial of Radium-223 (Ra-223) in Combination with Pembrolizumab in Patients (Pts) with Stage IV Non-Small Cell Lung Cancer (NSCLC).” In ANNALS OF ONCOLOGY, 31:S897–S898. Amsterdam: Elsevier. doi:10.1016/j.annonc.2020.08.1734.
Vancouver
1.
Reck M, Mileham KF, Clump DA, Decoster L, Estival A, Felip E, et al. A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC). In: ANNALS OF ONCOLOGY. Amsterdam: Elsevier; 2020. p. S897–8.
IEEE
[1]
M. Reck et al., “A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC),” in ANNALS OF ONCOLOGY, ELECTR NETWORK, 2020, vol. 31, no. Suppl 4, pp. S897–S898.
@inproceedings{8680396,
  articleno    = {{Abstract: 1420TiP}},
  author       = {{Reck, M. and Mileham, K. F. and Clump, D. A. and Decoster, L. and Estival, A. and Felip, E. and Fried, P. and Paz-Ares, L. and Sebastian, M. and Vinolas Segarra, N and Surmont, Veerle and Wagner, A. and Galdy, S. M. and Smit, E. F.}},
  booktitle    = {{ANNALS OF ONCOLOGY}},
  issn         = {{0923-7534}},
  language     = {{eng}},
  location     = {{ELECTR NETWORK}},
  number       = {{Suppl 4}},
  pages        = {{Abstract: 1420TiP:S897--Abstract: 1420TiP:S898}},
  publisher    = {{Elsevier}},
  title        = {{A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)}},
  url          = {{http://doi.org/10.1016/j.annonc.2020.08.1734}},
  volume       = {{31}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: